Glenmark Pharmaceuticals Announces Board Meeting to Approve Q1 Unaudited Results; Trading Window Remains Closed
Glenmark Pharmaceuticals Ltd has announced that its Board of Directors will convene a meeting to review and approve the Unaudited Financial Results for the quarter ended June 30, 2026. The results, covering both Standalone and Consolidated figures, are scheduled for consideration at the board meeting on Friday, July 31, 2026.Following the conclusion of this board meeting, Glenmark Pharmaceuticals will submit its Unaudited Financial Results to the Stock Exchanges on July 31, 2026.
In observance of the Company's Code of Conduct for Prevention of Insider Trading, Glenmark Pharmaceuticals confirmed that a trading window restriction is in effect regarding the upcoming results. The ban applies to Designated Persons, which include Directors, Key Managerial Personnel, Identified Employees/Persons, and their Immediate Relatives or Connected Persons.
The trading window for these securities was closed on July 01, 2026. It will remain closed until the expiry of 48 hours after the declaration of the Unaudited Financial results for the quarter ended June 30, 2026. Consequently, the trading window is set to reopen on Monday, August 03, 2026.
The timeline for key corporate events related to the financial performance is summarized below:
| Event | Date/Period |
|---|---|
| Board Meeting to Approve Results | Friday, July 31, 2026 |
| Submission of Unaudited Financial Results | Following the board meeting on July 31, 2026 |
| Insider Trading Window Closed From | July 01, 2026 |
| Insider Trading Window Reopens | Monday, August 03, 2026 |
GLENMARK Stock Price Movement
Shares of Glenmark Pharmaceuticals Limited slipped slightly in post-market trading today, settling at ₹2304.2 after shedding 0.04%. The stock moved within an intraday range of ₹2285.6 to ₹2318.9, amid a volume of 491,363 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.